Orbis Biosciences, Inc.

FogPharma ended 2022 with a big cash haul – $178m from a series D venture capital round – and in 2023 achieved a couple of big milestones that helped the company raise its next big financing this yea

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in